111 related articles for article (PubMed ID: 10218511)
21. Immune suppression in renal cell carcinoma.
Frankenberger B; Noessner E; Schendel DJ
Semin Cancer Biol; 2007 Aug; 17(4):330-43. PubMed ID: 17656104
[TBL] [Abstract][Full Text] [Related]
22. T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma.
Warren EH; Tykodi SS; Murata M; Sandmaier BM; Storb R; Jaffee E; Childs R; Thompson JA; Greenberg PD; Riddell SR
Cytotherapy; 2002; 4(5):441. PubMed ID: 12473218
[No Abstract] [Full Text] [Related]
23. Mechanisms of immune dysfunction in renal cell carcinoma.
Derweesh IH; Tannenbaum CS; Rayman PA; Finke JH
Cancer Treat Res; 2003; 116():29-51. PubMed ID: 14650824
[No Abstract] [Full Text] [Related]
24. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
[TBL] [Abstract][Full Text] [Related]
26. Lymphocyte therapy of renal cell carcinoma.
Dillman RO
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
[TBL] [Abstract][Full Text] [Related]
27. Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function.
Gati A; Guerra N; Giron-Michel J; Azzarone B; Angevin E; Moretta A; Chouaib S; Caignard A
Cancer Res; 2001 Apr; 61(8):3240-4. PubMed ID: 11309272
[TBL] [Abstract][Full Text] [Related]
28. T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.
Schroten C; Kraaij R; Veldhoven JL; Berrevoets CA; den Bakker MA; Ma Q; Sadelain M; Bangma CH; Willemsen RA; Debets R
J Immunol Methods; 2010 Jul; 359(1-2):11-20. PubMed ID: 20460126
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation with clinical and histopathological data.
Brasanac D; Marković-Lipkovski J; Hadzi-Djokić J; Müller GA; Müller CA
Neoplasma; 1999; 46(3):173-8. PubMed ID: 10613593
[TBL] [Abstract][Full Text] [Related]
30. VHL-dependent alterations in the secretome of renal cell carcinoma: Association with immune cell response?
Stehle F; Leisz S; Schulz K; Schwurack N; Weber N; Massa C; Kalich J; Fahldieck C; Seliger B
Oncotarget; 2015 Dec; 6(41):43420-37. PubMed ID: 26486078
[TBL] [Abstract][Full Text] [Related]
31. A novel co-stimulatory T cell antigen co-expressed on renal cell carcinoma.
Labuda T; Lando P; Björkdahl O; Kalland T; Vessella R; Hedlund G; Eriksson H; Sjögren HO; Dohlsten M
Int Immunol; 1995 Sep; 7(9):1425-32. PubMed ID: 7495750
[TBL] [Abstract][Full Text] [Related]
32. Tumor-induced dysfunction in T lymphocytes: increased sensitivity to apoptosis.
Finke JH; Tannenbaum C; Storkus W; Rayman P; Das T; Biswas K; Richmond A; Moon C; Thornton M; Gill I; Novick A; Bukowski R
Urologe A; 2004 Sep; 43 Suppl 3():S131-2. PubMed ID: 15148573
[No Abstract] [Full Text] [Related]
33. Correspondence re: J. P. Alexander et al., T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res., 53: 1380-1387, 1993.
Whiteside TL
Cancer Res; 1993 Dec; 53(23):5828. PubMed ID: 8242642
[No Abstract] [Full Text] [Related]
34. Immunosuppressive factor derived from renal cancer cells.
Muraki J; Fischer J; Addonizio JC; Nagamatsu GR; Chiao JW
Urology; 1989 Oct; 34(4):205-9. PubMed ID: 2800085
[TBL] [Abstract][Full Text] [Related]
35. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas.
Kolenko V; Wang Q; Riedy MC; O'Shea J; Ritz J; Cathcart MK; Rayman P; Tubbs R; Edinger M; Novick A; Bukowski R; Finke J
J Immunol; 1997 Sep; 159(6):3057-67. PubMed ID: 9300731
[TBL] [Abstract][Full Text] [Related]
36. [ I.Renal cell carcinoma].
Tomita Y
Gan To Kagaku Ryoho; 2014 Jan; 41(1):38-41. PubMed ID: 24796020
[No Abstract] [Full Text] [Related]
37. Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk.
Cabillic F; Bouet-Toussaint F; Toutirais O; Rioux-Leclercq N; Fergelot P; de la Pintière CT; Genetet N; Patard JJ; Catros-Quemener V
Clin Exp Immunol; 2006 Dec; 146(3):518-23. PubMed ID: 17100773
[TBL] [Abstract][Full Text] [Related]
38. Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
Mulders P
Eur Urol; 2009 Jul; 56(1):132-3. PubMed ID: 18550266
[No Abstract] [Full Text] [Related]
39. Human renal cell carcinoma inhibits dendritic cell maturation and functions.
Song EY; Shurin MR; Tourkova IL; Chatta G; Shurin GV
Urologe A; 2004 Sep; 43 Suppl 3():S128-30. PubMed ID: 15150693
[No Abstract] [Full Text] [Related]
40. [Renal cell carcinoma with non-specific Ig-G antibody and its treatment].
Miyakita H; Nagata Y; Kinoshita H; Kawamura N; Hida M
Nihon Hinyokika Gakkai Zasshi; 1985 Aug; 76(8):1234-8. PubMed ID: 4094266
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
